Download the slides

---

Related articles :

• Studies 1216 and 1160

---

Table of contents

Switch to RPV/FTC/TAF
Studies 1216 and 1160
Original article : Orkin C. HIV Drug Therapy 2016, Glasgow, Abs. O124
Dernière mise à jour : 02/01/2017

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

• Switching to RPV/FTC/TAF from RPV/FTC/TDF or EFV/FTC/TDF was effective
  • High rates of virologic suppression
  • No emergent resistance mutations on RPV/FTC/TAF
• RPV/FTC/TAF was well tolerated
  • Low rate of adverse events
  • Low rate of discontinuation
• RPV/FTC/TAF provided improved renal and bone safety
  • Decreased total and tubular proteinuria (p < 0.001)
  • No proximal tubulopathy
  • Increased BMD at hip and spine (p < 0.001)

Design

Objective

• Primary Endpoint: proportion with treatment success at W48 (HIV RNA < 50 c/mL, ITT- FDA snapshot)

Baseline characteristics

HIV-1 RNA < 50 c/mL at W48 (ITT, FDA snapshot)

Adverse events, % (≥ 5% in either group)

Adverse events leading to discontinuation, N (%)

Grade 3-4 laboratory abnormalities, %

Median change in eGFR [ Cockroft-Gault ] (mL/min) at W48 (Q1-Q3)

Change in Proteinuria at W48 (median % change)

• All differences (RPV/F/TAF vs RPV/F/TDF or EFV/F/TDF) : p < 0.001 ; no reported cases of tubulopathy

Median % change in Hip BMD through W48 (95% CI)

Median % change in Spine BMD through W48 (95% CI)

Median fasting lipids (mg/dL) at baseline and W48

Median fasting lipids (mg/dL) at baseline and W48

Back to Table of Contents